Holen Sie sich die Stockscreener-App
12.78
5.75%
-0.78
Handel nachbörslich:
12.80
0.02
+0.16%
Schlusskurs vom Vortag:
$13.56
Offen:
$13.41
24-Stunden-Volumen:
793.93K
Relative Volume:
0.49
Marktkapitalisierung:
$280.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-112.46M
KGV:
-7.7927
EPS:
-1.64
Netto-Cashflow:
$-99.89M
1W Leistung:
-2.29%
1M Leistung:
+52.87%
6M Leistung:
-73.38%
1J Leistung:
-60.80%
1-Tages-Spanne:
$12.58
$13.56
1-Wochen-Bereich:
$10.29
$13.88
52-Wochen-Spanne:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
500 BOYLSTON STREET, BOSTON
Vergleichen Sie VOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
12.78 | 297.11M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Eingeleitet | TD Cowen | Buy |
| 2025-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2025-11-25 | Fortgesetzt | Wedbush | Neutral |
| 2025-10-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | Hochstufung | Stifel | Hold → Buy |
| 2025-06-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
Will Vor Biopharma Inc. stock return to pre crisis levelsMarket Sentiment Report & Community Consensus Picks - ulpravda.ru
How Vor Biopharma Inc. stock valuations compare to rivals2025 Year in Review & High Accuracy Swing Entry Alerts - ulpravda.ru
Why Vor Biopharma Inc. stock remains a top recommendationTrade Volume Report & Stock Timing and Entry Methods - ulpravda.ru
How Vor Biopharma Inc. stock responds to policy changes2025 EndofYear Setup & Growth Focused Investment Plans - ulpravda.ru
Why Vor Biopharma Inc. stock is a must watch in 2025Market Rally & Stepwise Entry and Exit Trade Signals - ulpravda.ru
How Vor Biopharma Inc. stock benefits from global expansionMonthly Performance Summary & Start Small. End Wealthy. - bollywoodhelpline.com
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference - MarketScreener
What drives Vor Biopharma Inc stock priceInstitutional Buying Trends & Low Entry Cost Trading - earlytimes.in
Ariose Capital Management Ltd Invests $5.37 Million in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc Stock Analysis and ForecastSell Signals and Alerts & Free High Yield Growth Strategies - earlytimes.in
Aug Macro: Will Vor Biopharma Inc stock outperform international peersFed Meeting & Verified Momentum Stock Watchlist - moha.gov.vn
Vor Biopharma CDO Departs, Transition Support Planned - TipRanks
Vor Biopharma Target of Unusually High Options Trading (NASDAQ:VOR) - MarketBeat
Portfolio Update: How Vor Biopharma Inc. stock benefits from global expansionTrade Risk Report & Fast Entry and Exit Trade Plans - moha.gov.vn
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors - ts2.tech
Gap Down: Is Vor Biopharma Inc stock positioned well for digital economyJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - moha.gov.vn
Vor Biopharma (VOR) Stock Analysis Report | Financials & Insights - Benzinga
Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Moving Averages: How strong is Celsius Holdings Inc stock balance sheet2025 Short Interest & Community Verified Swing Trade Signals - moha.gov.vn
Vor Biopharma Stock (+7.4%): New Board Signals Institutional Backing - Trefis
Vor Biopharma Inc. (NASDAQ:VOR) Sees Large Growth in Short Interest - MarketBeat
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors - The Globe and Mail
Vor Biopharma adds two investment partners to board of directors By Investing.com - Investing.com Nigeria
Vor Biopharma Inc Announces Board Appointments - marketscreener.com
Vor Biopharma Inc.(NasdaqGS: VOR) added to NASDAQ Biotechnology Index - marketscreener.com
VOR: JP Morgan Lowers Price Target While Maintaining Overweight Rating | VOR Stock News - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Why Vor Biopharma Inc. stock appeals to dividend seekersJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - ulpravda.ru
Vor Biopharma Signs Multiple Financing Agreements - TradingView — Track All Markets
Vor Biopharma (VOR) secures $150M private placement and adds two directors - Stock Titan
Technical Analysis: Will Vor Biopharma Inc. stock reach all time highs in 2025Earnings Performance Report & Accurate Technical Buy Alerts - Улправда
Vor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpoint - MSN
Vor Biopharma: Initiating Hold Rating On Durable Telitacicept MG Study Data - Seeking Alpha
Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential By Investing.com - Investing.com South Africa
VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus
Vor Biopharma (NASDAQ:VOR) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Stocks to watch: Vor Biopharma sees RS rating jump to 89 - MSN
TD Cowen Initiates Vor Biopharma at Buy - marketscreener.com
Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential - Investing.com Australia
TD Cowen Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
Vor Biopharma’s Surge: New Opportunities? - StocksToTrade
HC Wainwright & Co. Maintains Vor Biopharma (VOR) Buy Recommendation - MSN
Aug Chart Watch: Why Vor Biopharma Inc stock remains resilientPortfolio Performance Report & Free Technical Confirmation Trade Alerts - moha.gov.vn
Vor Biopharma Launches $150 Million Private Placement; Shares Rise - marketscreener.com
Vor Bio announces $150 million private placement - marketscreener.com
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):